Universität zu Köln

Sasse, S., Behringer, K., Semrau, R. and Engert, A. (2014). Controversies in the treatment of early and intermediate stage Hodgkin's lymphoma. Onkologe, 20 (5). S. 448 - 455. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Full text not available from this repository.

Abstract

With combined modality treatment which includes a polychemotherapy regimen and a consolidating IF-radiotherapy strategy long-term remission rates of about 85% can be achieved in early favorable and unfavorable HL patients. International points of discussion are the role of the consolidating radiotherapy and the optimal chemotherapy regimen for patients with early unfavorable HL. Current treatment approaches aim at further reduction of radiotherapy field size and at optimizing of the chemotherapy regimens and additionally evaluate PET-response based radiotherapy approaches in order to reduce treatment-associated toxicity, while maintaining treatment efficacy. Deduction of the GHSG-standard and discussion of current trials in early favorable and unfavourable HL patients. Two courses of ABVD followed by 20 Gy IF-RT have to be regarded as standard of care in early favorable HL, and four courses of chemotherapy followed by 30 Gy IF-RT are standard in early unfavorable HL. So far, the available data to a PET-response guided radiotherapy approach do not permit to omit the consolidating radiotherapy. In early unfavorable HL, 2+2 results in a significantly improved tumor control compared to four courses of ABVD and is therefore recommended by the GHSG as standard chemotherapy regimen in patients with early unfavorable HL. The ongoing HD16 and HD17 trials are designed to answer the question whether radiotherapy can be omitted in those patients with a negative PET response after completion of chemotherapy. By implementing brentuximab vedotin in the first line treatment of early favorable and unfavorable HL we might achieve a further reduction of treatment-associated toxicity.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sasse, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Behringer, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Semrau, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-439201
DOI:	10.1007/s00761-013-2636-4
Journal or Publication Title:	Onkologe
Volume:	20
Number:	5
Page Range:	S. 448 - 455
Date:	2014
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0415
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INVOLVED-FIELD RADIOTHERAPY; CHEMOTHERAPY; VINBLASTINE; IRRADIATION; DOXORUBICIN; RADIATION; THERAPY; DISEASE Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/43920